Can Peptide Companies Advertise on Google Ads? (Nov 2026)

Key takeaways

Some can, some can’t. The deciding factors are your business type, the product, and how your site describes it. Google makes the final call on every account.
There is no single “peptide policy.” Peptide advertisers get judged by several overlapping policies at once — Healthcare and Medicines, Unapproved Substances, Misrepresentation, and Merchant Center product data policy.
What you sell matters less than how your site presents it. Identical products pass or fail depending on claims, labelling, checkout gating, and documentation.
Research-use suppliers, telehealth clinics, and compounding pharmacies each take a different approval path. Copying another company’s setup is one of the most common reasons for suspension.
Approval is a website and data problem first, a campaign problem second.

The short answer

Some peptide companies can advertise on Google Ads, and some can’t. What decides it is the type of business, the specific product, and how the website presents it. Google makes the final call on every account, domain and product, so nobody can promise you an outcome.

If you are a…	Main policy question	Read next
Research-use peptide supplier	Unapproved substances and misrepresentation. A research-use-only label alone doesn’t settle it.	Google Ads for research peptides
Telehealth provider that prescribes	Google healthcare certification (LegitScript first)	LegitScript and Google Ads
Compounding pharmacy	Pharmacy certification and prescription drug terms	Advertising compounded GLP‑1s
Wholesale / B2B supplier	Misrepresentation and buyer intent	Merchant Center for peptides

That answer sounds unsatisfying until you understand what actually drives it. Google isn’t evaluating “peptides” as a category with a yes/no switch. It is evaluating a set of signals across your website, your product data, your claims and your business entity, then applying several policies simultaneously. Two companies selling the same molecule at the same price can land in completely different places because one of them reads as a documented supplier and the other reads as an unapproved-substance seller making health claims.

What we mean by “peptide company”

This article covers research-use peptide suppliers, telehealth and wellness clinics prescribing peptide therapies, compounding pharmacies, wholesale suppliers, and manufacturers. Those are five different advertising problems that get lumped into one word.

Which policies actually apply

Most agencies quote one policy and stop. In practice, peptide accounts are reviewed against several at once:

Healthcare and medicines. Governs prescription drug promotion, pharmacy certification, and which advertiser types may promote which treatments in which countries. Relevant if there is any prescribing, telehealth or pharmacy relationship.
Unapproved substances. The policy most peptide advertisers actually collide with. Speculative, experimental or non-approved substances are restricted, and language that implies human consumption pushes a product into this bucket fast.
Misrepresentation. The quiet account-killer. Missing business identity, thin contact information, unclear refund and shipping terms, unverifiable certifications, or implied outcomes without support.
Merchant Center product data policy. Applies to Shopping and Performance Max. Product titles, attributes, images and landing pages are all reviewed as data, not just as marketing.
Local legal requirements. Country-level rules layered on top of Google’s own. A setup that clears in one market can be refused in another.

Because the policies overlap, a single fix rarely resolves a suspension. A site can be perfectly clean on medical claims and still be disapproved for identity and transparency gaps.

Why presentation decides the outcome

The most useful mental model: Google’s reviewers and automated systems are trying to determine what your product is for. Everything on your site is evidence toward that determination.

Signals that push a listing toward “consumer therapeutic” treatment:

Dosage protocols, cycles, stacking guidance, or “how to use” content
Before/after imagery, weight-loss or performance outcomes, condition names
Reviews describing personal use
Bundling with syringes, bacteriostatic water, or injection supplies on the same page

Signals that support a documented research-supply reading:

Consistent research-use-only labelling on product pages, cart and checkout — not just in a footer disclaimer
Certificates of analysis, purity data, batch numbers, third-party testing published and accessible
Clear entity information: legal name, registered address, contact routes, policies
Product data that describes the compound and specification instead of an outcome

A common trap

Teams often clean the pages they intend to advertise and leave the rest of the site untouched. Reviews consider the domain, not the landing page. A single blog post about dosing can undo a compliant product catalogue.

What changed between October 2025 and November 2026

Prescription drug terms (October 2025). Google updated its Healthcare and medicines policy, with enforcement from 29 October 2025. Campaigns targeting the United States, Canada and New Zealand may now use prescription drug terms in ad text and landing pages in line with local law. Keyword-targeting those terms still requires certification, and online pharmacies, telemedicine providers and pharmaceutical manufacturers still need certification. Elsewhere, promotional use of these terms is not allowed.
Shopping policies merged (September 2026). Google combined its Shopping ads and free listings policies into one set of Shopping policies. Google says this doesn’t change what is allowed or how strictly it is enforced. Some rules still apply only to Shopping ads, and the help center labels them.
HHS peptide compounding policy (October 2026). HHS published an interim enforcement-discretion policy for 503A compounding with six peptide bulk substances: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. It sets conditions for compounding pharmacies. It isn’t a Google policy, and it doesn’t make these substances advertisable on Google. See our regulatory tracker for detail.

One rule that didn’t change: Google’s unapproved substances policy applies “regardless of any claims of legality,” and covers products marketed as safe or effective for preventing or treating a condition without government approval. Google’s example list is non-exhaustive, so a compound not being named on it doesn’t mean it’s allowed.

The four approval paths by business type

Business type	Primary risk	Typical viable route
Research peptide supplier	Unapproved substances, misrepresentation	Search on non-consumption intent, strict research-use presentation, documentation-heavy site, Shopping only after Merchant Center is stable
Telehealth / wellness clinic	Healthcare policy, certification requirements	Certification and entity verification first, service-level messaging, lead-gen structure with offline conversion tracking
Compounding pharmacy	Pharmacy certification, prescription claims	Pharmacy certification where applicable, brand and non-product terms, careful geographic scoping
Wholesale / manufacturer	Misrepresentation, B2B intent mismatch	B2B positioning, gated ordering, capability and specification content, Search plus retargeting rather than Shopping

Choosing the wrong path is expensive. A supplier that copies a telehealth clinic’s messaging inherits healthcare-policy exposure it cannot satisfy; a clinic that copies research-use language undermines the very certification it needs.

What to do before you launch anything

Full-site policy pass. Every product page, blog post, FAQ, review and image — not the landing page alone.
Entity and transparency review. Business identity, contact, shipping, returns and terms, all reachable in two clicks.
Documentation publishing. COAs, testing and specifications online and linkable.
Tracking before spend. Server-side or enhanced conversions, consent handling, and de-duplicated conversion actions so early data is usable.
Merchant Center diagnostics (if Shopping matters) before any feed submission at scale.
Then campaign structure and launch, starting narrow enough to survive a review cycle.

Want to know where you stand first? The Google Ads Readiness Score scores your business on these checks in about two minutes. If you’d rather talk it through, book a strategy call.

Sources

All sources were checked 6 November 2026.

Google Advertising Policies Help, Healthcare and medicines
Google Advertising Policies Help, Unapproved pharmaceuticals and supplements (non-exhaustive list)
Google Advertising Policies Help, Prescription drug services
Search Engine Roundtable, Google Ads updates its prescription drug terms policy (17 October 2025)
Google Merchant Center Help, Announcements change log (Shopping policy consolidation, posted 15 July 2026)
Federal Register, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (30 October 2026)

Founder Question

“Our competitor is running ads right now. Why can’t we just do what they’re doing?”

Our Perspective

Because you can only see their ads — not their entity verification status, their certifications, their Merchant Center history, or how many suspensions it took to get there. Copying visible output while missing the invisible configuration is how accounts inherit risk without inheriting the protections. We would rather map your own path than reverse-engineer someone else’s.

Practical Recommendation

Decide which of the five business types you actually are before writing a single ad — research supplier, telehealth clinic, compounding pharmacy, wholesaler or manufacturer. The approval path differs for each, and copying another company’s setup is the most common self-inflicted suspension.
Audit the whole domain, not the pages you plan to advertise. Reviews consider the site as a body of evidence about what your product is for, so legacy dosing content undoes a clean catalogue.
Sequence Search before Shopping. Search has a narrower review surface than Merchant Center product data, so it is usually the cheaper place to establish a stable account history.

What we learned

A check you can run yourself: search your own domain on Google for site:yourdomain.com plus words like dose, dosage, cycle, protocol, results and before. Every page that comes back is part of what a reviewer reads, not just the page your ads point to. If the pages tell different stories about what the product is for, fix that before launching anything.

Frequently asked

Is it against Google's rules to sell peptides?

Google doesn’t ban the word “peptide.” Its unapproved substances policy applies regardless of claims of legality, though, and it covers products marketed as safe or effective for a condition without government approval. A research-use-only label alone doesn’t take a product outside that policy. What the product is and how the whole site presents it decide the outcome.

Did Google change its peptide policy in 2026?

Google hasn’t published a peptide-specific policy change. The changes that matter are the October 2025 update on prescription drug terms and the September 2026 merge of the Shopping policies, which Google says changed no rules. The October 2026 HHS compounding policy applies to pharmacies, not to Google Ads.

Can I run Search ads but not Shopping?

Often yes, and it is frequently the right sequence. Search has a narrower review surface than Merchant Center product data, so many accounts stabilise on Search first and add Shopping later.

Will using a different domain solve a suspension?

No. Domain switching without fixing the underlying signals is treated as circumvention, which escalates the problem rather than resolving it.

Next step

If you want this applied to your account and your site rather than read in the abstract, book a 30-minute strategy session. We will look at the domain before the call.

Book a Strategy Call

Can Peptide Companies Advertise on Google Ads? (Updated November 2026)